-
Mesothelioma Lawsuit Reveals Lack of Oversight From Talc Product Company
At the heart of every mesothelioma lawsuit is the question of whether the asbestos product company being sued was negligent or reckless. That issue was on full display this week as a New Jersey jury heard an executive from the company that sold Clubman talcum powder admit that the company had never bothered to conduct
-
Mesothelioma Conference Impacted by Coronavirus Fears
As concerns about the coronavirus pandemic spread around the world, its impact is being felt within the community of mesothelioma patients and researchers alike. As medical professionals take measures to protect already vulnerable patients from exposure to those who may unknowingly carry the virus, researchers working towards a cure for the rare and fatal form
-
Jury Awards Elderly Woman $9 Million in Johnson & Johnson’s Baby Powder Mesothelioma Lawsuit
Johnson & Johnson continues to defend itself against accusations of causing malignant mesothelioma, but the company has increasingly seen juries deciding against it and awarding significant juries to victims who claim that asbestos their talc-based powders caused their illness. The most recent verdict was handed down by a Florida jury that awarded 82-year-old Blanca Moure-Cabrera
-
Talc Mesothelioma Lawsuits Extend to Revlon Over Popular Body Powder
The talc mesothelioma lawsuits that have been capturing the public’s attention have largely centered around claims against Johnson & Johnson over their popular baby powder product. But a recent case filed in New York state court has evoked yet another familiar brand name, as a husband and wife blame Revlon’s Jean Nate talcum powder products
-
Study of Women With Mesothelioma Links Disease With History of Exposure to Asbestos Worker
The cause of malignant mesothelioma has long been known: the rare and fatal form of cancer is caused by exposure to asbestos. But few studies have specifically looked at women diagnosed with the condition, and where their exposure came from. Now a study published in the American Journal of Surgical Pathology has demonstrated that most
-
Italian Study Provides Valuable Insights on Peritoneal Mesothelioma Risk
There are many types of cancer that, like malignant mesothelioma, are caused by exposure to some type of carcinogenic material. Benzene exposure can lead to leukemia; BPA exposure can lead to breast cancer; and obviously, nicotine and tobacco products can lead to lung cancer. In most cases, the more time has elapsed since last exposure,
-
Asbestos In MTA Bus Depot Raises Mesothelioma Fears for Employees and Students
In the long list of occupations that put people at risk for malignant mesothelioma, you’d be hard pressed to find public transit bus employee. Yet there are thousands of New York transit employees who recently learned that they were subjected to decades of asbestos exposure at New York MTA’s East New York bus depot in
-
Thai Asbestos Study Reveals The Relentless Risk of Mesothelioma
It’s long been known that asbestos is a carcinogenic material, and that it has caused countless deaths from malignant mesothelioma, as well as other serious illnesses including asbestosis and asbestos-related lung cancer. While efforts have been made internationally to reduce the use of the mineral, a recent study conducted in Thailand revealed just how difficult
-
Facing 1,700 Mesothelioma Deaths in 50 Years, Colombia Readies for Asbestos Ban
Facing increasing pressure and the harsh reality of tragic mesothelioma and asbestos-related disease deaths in their country, the government of Colombia instituted a full ban on all use of asbestos. The battle had been waged for twelve years when the Latin American country’s House of Representatives voted unanimously to stop asbestos use, mining and export.
-
New Mesothelioma Drug Option To Become Available in 2022
In a notable development for patients diagnosed with unresectable malignant mesothelioma, the U.S. Food and Drug Administration has given its approval for a new version of the chemotherapy drug pemetrexed to be used in the treatment of the rare and fatal form of cancer. Pemetrexed, which is sold under the brand name Alimta and manufactured
-
UK Study Points To Impact of Successful Talc Pleurodesis
Patients diagnosed with malignant pleural mesothelioma have access to numerous therapies that can both extend their survival and improve their quality of life. One of the most effective of these is talc pleurodesis, a procedure that involves draining lung fluid — called pleural effusions — that has accumulated in the layers of the pleura and
-
Italian Researchers Report Impressive Response to Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma
A study published in a recent issue of the medical journal Lung Cancer reports that Italian cancer researchers have reported that use of immune checkpoint inhibitors yielded successful antitumor activity in a patient diagnosed with malignant pleural mesothelioma.
-
Johnson & Johnson Settles Another Mesothelioma Lawsuit
Johnson & Johnson’s Baby Powder has been named as a defendant in over 16,000 lawsuits accusing the company’s product of asbestos contamination. In some cases the plaintiffs are seeking damages over a malignant mesothelioma diagnosis while in others they’ve been impacted by ovarian cancer, but in nearly all of the legal battles the company has
-
After Multiple Mesothelioma Lawsuits, Prop 65 Claim Filed Against Johnson & Johnson & Others
With new mesothelioma and ovarian cancers being filed every day against Johnson & Johnson and other talc product manufacturers, a new legal attack has been launched under California’s Prop65 law. A lawsuit has been filed accusing Johnson & Johnson, the maker of Gold Bond talc powder, manufacturers of generic talc products and retailers of failing
-
Mesothelioma Researchers Remain Uncertain About Combining Chemotherapy and Immunotherapy
In the face of a disease as challenging as malignant mesothelioma, it is easy to understand why patients and physicians alike would be tempted to use every available tool to bombard the cancer’s cells in the hopes of eradicating it or extending survival time. Unfortunately, what feels like it makes the most sense may not
-
Are Mesothelioma Patients Leaving An Effective Treatment on the Table?
Many patients diagnosed with malignant mesothelioma are skipping or abandoning a treatment protocol that could extend their lives by several months, and researchers from MD Anderson are trying to determine why. The protocol is Intensity Modulated Radiotherapy (IMRT), a type of targeted radiation that sends powerful radiotherapy beams directly into malignant tumors, leaving surrounding tissue
-
Researchers Express Fears That Superbugs Could Impact Mesothelioma Treatment
As mesothelioma researchers search for the best possible combination of treatments to slow and stop the spread of the rare and always-fatal form of cancer, oncologists in the United Kingdom and United States are raising fears that all of their efforts could be foiled by the rise of “superbugs” that would remove chemotherapy as a
-
Mesothelioma Risk Drives Fire Department Diligence
Name the occupations that are naturally associated with heroism and courage and firefighter is likely to top the list, but when asked to name the risks associated with firefighting, few people are likely to come up with malignant mesothelioma. Yet firefighters are at far greater risk for the rare asbestos-related form of cancer than the
-
New York Mesothelioma Lawsuit Pits Con Ed Against Family of Deceased Backhoe Operator
A mesothelioma lawsuit that’s making its way through the New York Asbestos Litigation courts is pitting the family of a deceased backhoe operator against the legal power of Consolidated Edison, and the victim’s family has won the first round.
-
UK Researchers Validate Pleural Mesothelioma Grading System
As medical science learns more about malignant mesothelioma, the frustrations in treating the illness have grown. Though more is understood about the condition and its causes, its prognosis remains poor, with overall survival hovering between 9 and 12 months for most patients. Among those eligible for surgical interventions, the median survival increases to between ten
